|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
High tumor mutational burden (TMB) and PD-L1 expression are leading biomarkers in metastatic non-small cell lung cancer (NSCLC) and predict favorable response to checkpoint inhibitors.
|
31550464 |
2020 |
|
Metastatic non-small cell lung cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels.
|
31610828 |
2020 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Male, ever-smoker and positive PD-L1 are indicative of benefit to ICIs in metastatic non-small-cell lung cancer.
|
30730276 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
|
30515719 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Case presentation:</b> A 66-year-old gentleman with metastatic non-small-cell lung cancer developed a wide-based gait following treatment on a clinical trial with cytotoxic chemotherapy and an anti-PD-L1 drug.
|
31414604 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Atezolizumab (Tecentriq<sup>®</sup>), a humanized, anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody, in combination with bevacizumab, carboplatin and paclitaxel (ABCP) or with carboplatin and nab-paclitaxel (ACnP) has been approved as first-line treatment for metastatic nonsquamous NSCLC, based on results from the randomized IMpower150 and IMpower130 studies in chemotherapy-naïve patients with nonsquamous metastatic NSCLC.
|
31728860 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 expression by immunohistochemistry (IHC) testing with Tumor Proportion Score (TPS) ≥50% and ≥1% is required to be eligible for first- and second-line Pembrolizumab treatment for metastatic non-small cell lung cancer (NSCLC) respectively.
|
31097091 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, all patients with metastatic non-small cell lung cancer should undergo molecular testing for relevant mutations and expression of the protein PD-L1 (programmed death ligand 1).
|
31454018 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Case 2, reported here, is a 68-year-old woman with stage IV non-small cell lung cancer whose tumor was positive for the programmed death ligand-1 (PD-L1) marker.
|
30952734 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
For the use of immunotherapy in metastatic non-small cell lung cancer (NSCLC), the NCCN Guidelines for NSCLC reflect the importance of assessing levels of PD-L1 expression to determine the best use of PD-1/PD-L1 inhibitors, whether alone or in combination with chemotherapy.
|
31117034 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices.
|
31774363 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-PD-1/PDL-1 ICIs showed promising efficacy (~30% response rate) and improved the survival of patients with metastatic NSCLC, but the role of anti-PD-1/PDL-1 ICIs for EGFR mutant NSCLC is not clear.
|
31387256 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immune checkpoint inhibition of programmed-death receptor 1 (PD-1) or its ligand (PD-L1) has become a standard in the treatment of metastatic non-small cell lung cancer, either as monotherapy or in combination.
|
31749060 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
|
30955977 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antibodies that target programmed death 1 (PD-1) or its ligand (programmed death ligand 1 (PD-L1) have become a mainstay of first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC) without targetable genetic alterations.
|
30912805 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
More recently, three anti-PD-L1 antibodies have received approval: atezolizumab and durvalumab for locally advanced or metastatic urothelial carcinoma and metastatic non-small cell lung cancer (NSCLC) and avelumab for the treatment of locally advanced or metastatic urothelial carcinoma and metastatic Merkel cell carcinoma.
|
30747264 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the KEYNOTE-024 trial, pembrolizumab demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) versus Standard-of-Care (SoC) platinum-based doublets for first-line treatment of PD-L1 -positive (≥50%) metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with no EGFR mutations or ALK translocations.
|
30642550 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-(L)1-blocking antibodies have clinical activity in metastatic non-small cell lung cancer (NSCLC) and mediate durable tumor remissions.
|
30765392 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
|
31319978 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eligible patients had confirmed locally advanced/metastatic NSCLC and provided a contemporaneous tumor sample for PD-L1 evaluation by immunohistochemistry using the 22C3 antibody.
|
31154919 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Background:</b> Immunotherapy that targets programmed death protein-1 (PD-1) provides improved treatment efficacy and survival in patients with metastatic non-small cell lung cancer (NSCLC), especially those with high tumor expression of PD-L1.
|
29805708 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-1/PD-L1 immune checkpoint inhibitors have demonstrated unprecedented efficacy in patients with stage IV NSCLC.
|
29358503 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of anti-PD-1/PD-L1 and CTLA-4 monoclonal antibody agents have been evaluated in metastatic non-small cell lung cancer.
|
29951301 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Atezolizumab is a programmed death ligand 1 (PDL-1) blocking antibody that was approved for metastatic non-small cell lung cancer (NSCLC) in patients with disease progression.
|
30087855 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have been approved as a standard therapy for metastatic non-small cell lung cancer (NSCLC).
|
29549910 |
2018 |